NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Balk EM, Ellis AG, Di M, et al. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Jun. (Comparative Effectiveness Reviews, No. 191.)
Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update [Internet].
Show detailsTable B1Excluded studies
| PubMed ID | Authors | Title | Journal | Rejection Reason |
|---|---|---|---|---|
| 7706340 | Abdel-Salam A, Eyres K{Abdel-Salam, 1995 #111} | Effects of tourniquet during total knee arthroplasty: A prospective randomized study | J Bone Joint Surg 1995;77-B:250–3 | No intervention of interest |
| 24026260 | Adam SS and McDuffie JR and Lachiewicz PF and Ortel TL and Williams JW Jr{Adam, 2013 #28} | Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. | Duplicate publication (no additional data) | |
| 23808982 | Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI {Agnelli, 2013 #120} | Oral apixaban for the treatment of acute venous thromboembolism | N Engl J Med 2013;369:799e808 | Not population of interest |
| 18485453 | Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B {Agnelli, 2009 #121} | Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran | Thromb Res 2009; 123: 488–97 | Pre-2010 (presumably excluded by Uconn) |
| 17408408 | Agnelli G, et al {Agnelli, 2007 #122} | A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement | J Thromb Haemost 5 (4) (2007) 746–753 | Pre-2010 (presumably excluded by Uconn) |
| 23857692 | Akpinar EE and Hosgun D and Akan B and Ates C and Gulhan M {Akpinar, 2013 #31} | Does thromboprophylaxis prevent venous thromboembolism after major orthopedic surgery? | No comparison of interest | |
| EMBASE 70613300 | Anderson D R; Dunbar M; Venitolli P A; Kahn S; Belzile E; Bohm E; Fisher W; Gross P; Kim P; Gofton W; MacDonald S; Pelet S; Crowther M; Pleasance S; Rodger M; Wells P; Kovacs M; Andreou P {Anderson, 2011 #123} | A randomized controlled trial comparing aspirin with dalteparin for the prevention of venous thromboembolism following total hip arthroplasty (2011) | Journal of thrombosis and haemostasis : JTH, 2011, 9, 303 | Duplicate publication (no additional data) |
| NCT01720108 | Anderson DR | Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II) (2012) | https: | No results reported |
| 23732713 | Anderson DR1, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, Fisher W, Gofton W, Gross P, Pelet S, Crowther M, MacDonald S, Kim P, Pleasance S, Davis N, Andreou P, Wells P, Kovacs M, Rodger MA, Ramsay T, Carrier M, Vendittoli PA. {Anderson, 2013 #35} | Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial | Ann Intern Med. 2013 Jun 4;158(11):800–6 | Not primary study |
| 24384784 | Argun M and Oner M and Saglamoglu M and Karaman I and Guney A and Halici M and Halil Kafadar I {Argun, 2013 #21} | Fondaparinux versus nadroparin for prevention of venous thromboembolism after elective hip and knee arthroplasty. | Combined TKR and THR | |
| noPMID 10 | Arti H; Rouzbahani R {Arti, 2013 #124} | Comparing the effectiveness results of heparin and enoxaparin after total hip artroplasty. [Persian] (2013) | Journal of Isfahan Medical School;Jun2013, Vol. 31 Issue 231, p381 | nRCS N<750 |
| 21053884 | Asensio A; Antolin F J; Sanchez-Garcia J M; Hidalgo O; Hernandez-Navarrete M J; Bishopberger C; Miguel L G; Gay-Pobes A; Cabrera-Quintero A; Asensio {Asensio, 2010 #81} | Timing of DVT prophylaxis and risk of postoperative knee prosthesis infection (2010) | Orthopedics | nRCS N<750 |
| CN-00441869 | Barden B, Kröger K, Löer F {Barden, 2001 #125} | Intraoperative Dopplersonography of the femoral vein for maintenance of venous flow in a hip endoprosthesis | Unfallchirurg 2001;104:138–42 | No intervention of interest |
| 23989471 | Barg {Barg, 2013 #30} | [Thromboembolic complications following ankle prosthesis implantation] | Not surgery of interest | |
| 24078351 | Barg {Barg, 2013 #27} | Thrombembolic complications after total ankle replacement | Not surgery of interest | |
| Barnes RW, Brand RA, Clarke W, Hartley N, Hoak JC {Barnes, 1978 #126} | Efficacy of graded-compression antiembolism stockings in patients undergoing total hip arthroplasty | Clinical Orthopaedics and Related Research 1978;132:61–7 | Pre-2010 (presumably excluded by Uconn) | |
| 25126354 | Baser O and Supina D and Sengupta N and Wang L {Baser, 2011 #73} | Anticoagulation Bridging Therapy Patterns in Patients Undergoing Total Hip or Total Knee Replacement in a US Health Plan: Real-World Observations and Implications. | nRCS N<750 | |
| noPMID 01 | Baser O; Wang L; Supina D; Sengupta N {Sengupta, 2011 #127} | Anticoagulation prophylaxis practice patterns in patients having total hip, total knee replacement in a US health plan (2011) | Formulary | nRCS N<750 |
| 26448724 | Bern M M; Hazel D; Deeran E; Richmond J R; Ward D M; Spitz D J; Mattingly D A; Bono J V; Berezin R H; Hou L; Miley G B; Bierbaum B E {Bern, 2015 #1} | Low dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study (2015) | Thromb J | Combined TKR and THR |
| Abstract P191 | Bern M M; Ward D; Miley G; Spitz D; Spigelman Z; Mattingly D; Williams F; Deeran E; Phillips C | Prospective randomized study of thromboembolic disease (TED) prophylaxis after knee or hip replacement: Fixed low dose warfarin vs. variable dose warfarin vs. fondaparinux, each given for 4 weeks (2010) | Pathophysiology of Haemostasis and Thrombosis | Duplicate publication (no additional data) |
| 23197272 | Beyer-Westendorf J and Lutzner J and Donath L and Tittl L and Knoth H and Radke OC and Kuhlisch E and Stange T and Hartmann A and Gunther KP and Weiss N and Werth S {Beyer-Westendorf, 2013 #46} | Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry. | Thromb Haemost. 2013 Jan;109(1):154–63 | Combined TKR and THR |
| 22882706 | Beyer-Westendorf J; Lutzner J; Donath L; Radke O C; Kuhlisch E; Hartmann A; Weiss N; Werth S {Beyer-Westendorf, 2012 #50} | Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: Findings from the ORTHO-TEP registry (2012) | J Thromb Haemost. 2012 Oct;10(10):2045–52 | Combined TKR and THR |
| Blanchard J, Meuwly JY, Leyvraz PF, et al {Blanchard, 1999 #128} | Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system | J Bone Joint Surg Br 1999;81:654 | Pre-2010 (presumably excluded by Uconn) | |
| Bradley JG, Krugener GH, Jager HJ {Bradley, 1993 #129} | The effectiveness of intermittent plantar venous compression in prevention of deep venous thrombosis after total hip arthroplasty | J Arthroplasty 1993;8:57–61 | Pre-2010 (presumably excluded by Uconn) | |
| Bruun-Olsen V, Heiberg KE, Mengshoel AM {Bruun-Olsen, 2009 #130} | Continuous passive motion as an adjunct to active exercises in early rehabilitation following total knee arthroplasty – a randomized controlled trial | Disability and Rehabilitation 2009;31(4):277–83 | Pre-2010 (presumably excluded by Uconn) | |
| Buller H, Deitchman D, Prins M, Segers A {Buller, 2008 #131} | Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis, The Botticelli DVT dose-ranging study | J Thromb Haemost 2008;6:1313e1318 | Pre-2010 (presumably excluded by Uconn) | |
| Cai wei | The Study of the Efficacy and Safety of VTE Prophylaxis with Rivaroxaban Following Total Hip Replacement | 2008, doi:CNKI:CDMD:1 2008 087675 | Pre-2010 (presumably excluded by Uconn) | |
| 27075710 | Camporese, G., Bernardi, E., Noventa, F., Bosco, M., Monteleone, G., Santoro, L., Bortoluzzi, C., Freguja, S., Nardin, M., Marullo, M., Zanon, G., Mazzola, C., Damiani, G., Maniscalco, P., Imberti, D., Lodigiani, C., Becattini, C., Tonello, C., Agnelli, G. {Camporese, 2016 #250} | Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study | Thromb Haemost | 27075710 |
| 20540254 | Cao J; Wang J; Zhang H; Wang L {Cao, 2010 #85} | [A combination of arteriovenous impulse system and low-molecular-weight heparins calcium for prophylaxis of deep venous thrombosis following total knee arthroplasty] (2010) | Zhongguo xiu fu chong jian wai ke za zhi = Chinese journal of reparative and reconstructive surgery | nRCS N<750 |
| 20812009 | Cao Y B; Zhang J D; Shen H; Jiang Y Y {Cao, 2010 #82} | Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials (2010) | Eur J Clin Pharmacol | Duplicate publication (no additional data) |
| Chan N; Li C; Lau K K; Chan A K C; Chan H H W {Chan, 2012 #132} | A systematic review evaluating the effects of treatment duration on bleeding due to factor-specific oral anticoagulant therapy (2012) | Blood. Conference: 54th Annual Meeting of the American Society of Hematology, ASH | SR or MA without references (conference abstract) | |
| 24813323 | Chapelle {Chapelle, 2014 #17} | Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials | Not surgery of interest | |
| 25724111 | Charters MA and Frisch NB and Wessell NM and Dobson C and Les CM and Silverton CD {Charters, 2015 #7} | Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty. | Combined TKR and THR | |
| Chen B, Zimmerman JR, Soulen L, DeLisa JA {Chen, 2000 #133} | Continuous passive motion after total knee arthroplasty: a prospective study | American Journal of PhysicalMedicine&Rehabililation 2000;79(5):421–6 | Pre-2010 (presumably excluded by Uconn) | |
| noPMID 05 | Chen J H; Xi Z L; Yuan Z{Chen J, #134} | Comprehensive prevention of deep vein thrombosis after total hip replacement. [Chinese] (2015) | China Tissue Engineering Research 2015, Vol 19. Issue (17) : 2642–2647 | Comparator mixed interventions |
| Abstract H5 | Cho S E; Clark N P; Delate T; Witt D M {Cho, 2011 #135} | Low-intensity warfarin thromboprophylaxis after hip replacement surgery (2011) | Journal of Thrombosis and Thrombolysis | No comparison of interest |
| 22387582 | Cohen A and Drost P and Marchant N and Mitchell S and Orme M and Rublee D and Simon TA and Sutton A {Cohen, 2012 #59} | The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. | Duplicate publication (no additional data) | |
| 70770566 | Cohen A; Pieter D; Marchant N; Mitchell S; Orme M; Simon T; Sutton A; Rublee D | The efficacy and safety of pharmacological prophylaxis of VTE following elective knee or hip replacement: Systematic review and network meta-analysis (2011) | Blood. Conference: 53rd Annual Meeting of the American Society of Hematology, ASH | SR or MA without references (conference abstract) |
| Cohen AT, Armstrong D, Gazdzik T, Ryge C, Pak R, Mandema J, et al | An adaptive-design dose-ranging study of PD 0348292, a new oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery [Abstract] | Blood 2008;112:361 Abstract 980 | Duplicate publication (no additional data) | |
| Cohen AT, Skinner JA, Warwick D, Brenkel I {Cohen, 2008 #136} | The use of graduated compression stockings in association with fondaparinux in surgery of the hip: A randomized, multinational, randomized, open-label, parallel-group comparative study | J Bone Joint Surg Br 2007; 89: 887–892 | Pre-2010 (presumably excluded by Uconn) | |
| 22441640 | Collinge CA and Kelly KC and Little B and Weaver T and Schuster RD {Collinge, 2012 #58} | The effects of clopidogrel (Plavix) and other oral anticoagulants on early hip fracture surgery. | nRCS N<750 | |
| 20201479 | Colwell {Colwell, 2009 #89} | The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty. | Orthopedics | No primary data |
| 24500578 | Colwell CW Jr and Froimson MI and Anseth SD and Giori NJ and Hamilton WG and Barrack RL and Buehler KC and Mont MA and Padgett DE and Pulido PA and Barnes CL | A mobile compression device for thrombosis prevention in hip and knee arthroplasty. | No comparison of interest | |
| Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, et al {Colwell, 2003 #137} | Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: A randomized, doubleblind study | Journal of Thrombosis and Haemostasis 2003;1 (10):2119–30 | Pre-2010 (presumably excluded by Uconn) | |
| Colwell CW Jr, Berkowitz SD, Lieberman JR, Comp PC, Ginsberg JS, Paiement G, et al {Colwell, 2005 #138} | Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty | Journal of Bone and Joint Surgery – American Volume 2005;87(10):2169–77 | Pre-2010 (presumably excluded by Uconn) | |
| Colwell CW Jr, Spiro TE {Colwell Jr, 1995 #139} | Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty | Clin Orthop Relat Res 1995; 319: 215–22 | Pre-2010 (presumably excluded by Uconn) | |
| Colwell CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al {Colwell, 2003 #140} | Randomized, doubleblind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B | Blood 2003;102(11):Abstract 39 | Pre-2010 (presumably excluded by Uconn) | |
| Colwell CW, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, et al | Randomized, doubleblind, comparison of Ximelagatran, an oral direct thrombin iInhibitor, and Enoxaparin to prevent venous thromboembolism (VTE) after total hip arthroplasty (THA) | Blood 2001;98(11):Abstract 2952 | Pre-2010 (presumably excluded by Uconn) | |
| Colwell CW. | EXULT B: More ximelagatran results in VTE prophylaxis after total knee replacement. | Abstract of the Annual Meeting of the American Society of Hematology (http://www | Pre-2010 (presumably excluded by Uconn) | |
| 22202495 | Dager {Dager, 2012 #65} | Warfarin for Venous Thromboembolism Prophylaxis After Elective Hip or Knee Arthroplasty: Exploring the Evidence, Guidelines, and Challenges Remaining | The Annals of Pharmacotherapy | No primary data |
| 20586919 | Dahl O E; Quinlan D J; Bergqvist D; Eikelboom J W {Dahl, 2010 #83} | A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty (2010) | J Thromb Haemost | Duplicate publication (no additional data) |
| Dahl O, Eriksson B, Agnelli G, Cohen A, Mouret P, Rosencher N, et al | ASA and NSAIDs with Melagatran/Ximelagatran or Enoxaparin Do NOT Increase Bleeding in Patients Undergoing Joint Replacement Surgery: The METHRO III Study | Journal of Thrombosis and Haemostasis 2005;3(1):Abstract P 1627 | Pre-2010 (presumably excluded by Uconn) | |
| Dahl OE, Eriksson BI, Agnelli G, Cohen AT, Mouret P, Rosencher N, et al | Postoperative melagatran/ximelagatran for the prevention of venous thromboembolism following major elective orthopaedic surgery: Effects of timing of first dose and risk factors for thromboembolism and bleeding complications on efficacy and safety | Clinical Drug Investigation 2005;25(1): 2005;25(1):65–77 | Pre-2010 (presumably excluded by Uconn) | |
| Darnell J B; Kleppinger E L {Darnell, 2011 #141} | Approved uses of dabigatran etexilate as an anticoagulant (2011) | Journal of Pharmacy Technology | No primary data | |
| 23300348 | Degli Esposti L and Didoni G and Simon T and Buda S and Sangiorgi D and Degli Esposti E {Degli Esposti, 2013 #45} | Analysis of disease patterns and cost of treatments for prevention of deep venous thrombosis after total knee or hip replacement: results from the Practice Analysis of Thromboprophylaxis after Orthopaedic Surgery (PATHOS) study. | No comparison of interest | |
| 21593017 | Deitelzweig S B; Lin J; Lin G {Deitelzweig, 2011 #76} | Preventing venous thromboembolism following orthopedic surgery in the United States: Impact of special populations on clinical outcomes (2011) | Clinical and Applied Thrombosis/Hemostasis | No comparison of interest |
| Abstract P201 | Deitelzweig S; Lin J; Lin G {Deitelzweig, 2011 #142} | Impact of special populations on thromboprophylaxis and clinical outcomes of patients undergoing knee replacement surgery in the US (2010) | Circulation: Cardiovascular Quality and Outcomes. Conference: Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke | No comparison of interest |
| Denis M, Moffet H, Caron F, Ouellet D, Paquet J, Nolet L {Denis, 2006 #143} | Effectiveness of continuous passive motion and conventional physical therapy after total knee arthroplasty: a randomized clinical | Physical Therapy 2006;86(2):174–85 | Pre-2010 (presumably excluded by Uconn) | |
| 70917349 | Dequen P; Kelly S; Abrams K {Dequen, 2012 #144} | Network meta-analysis of pharmacological interventions to prevent venous thromboembolism following elective knee and hip replacement surgery: Why extend the network? (2012) | Value in Health | SR or MA without references (conference abstract) |
| 25174484 | Ding G and Li S and Pan Z and Gao C and Ma H {Ding, 2014 #12} | [Effects of batroxobin on perioperative blood loss and coagulation in patients with low molecular weight heparin when undergoing the total hip replacement]. | Zhonghua Liu Xing Bing Xue Za Zhi. 2014 Jun;35(6):737–40. | No intervention of interest |
| 18056497 | Dorr LD, Gendelman V, Maheshwari AV, et al {Dorr, 2007 #96} | Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment | J Bone Joint Surg Am 2007;89:2648–57 | No comparison of interest |
| No PMID | Dose-confirmatory bridging study in total hip replacement. Available at: http://www | No results posted | Dose-confirmatory bridging study in total hip replacement. Available at: http://www | No results posted |
| 21272316 | Dranitsaris G and Jelincic V and Choe Y {Dranitsaris, 2011 #79} | Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement. | Duplicate publication (no additional data) | |
| 70514609 | Dranitsaris G; Jelincic V; Choe Y {Dranitsaris, 2011 #145} | Meta regression analysis to indirectly compare the safety and efficacy of dalteparin to enoxaparin for the prevention of venous thromboembolic events (VTES) in total hip replacement (THR) surgery (2010) | Value in Health | SR or MA without references (conference abstract) |
| Eisele R, Kinzl L, Koelsch T {Eisele, 2007 #146} | Rapid-inflation intermittent pneumatic compression for prevention of deep venous thrombosis | J Bone Joint Surg [Am] 2007;89-A:1050–1056 | Pre-2010 (presumably excluded by Uconn) | |
| Abstract P-TH-273 | Eriksson B I; Agnelli G; Gallus A S; Lassen M R; Prins M H; Renfurm R W; Turpie A G G {Eriksson, 2011 #147} | Onyx-3, a double-blind comparison of once- or twicedaily dosing with YM150 (30 or 60 mg daily) for preventing venous thromboembolism after elective hip arthroplasty (2011) | Journal of Thrombosis and Haemostasis | Duplicate publication (no additional data) |
| Abstract OC645 | Eriksson B; Dahl O E; Kurth A A; Hantel S; Huo M H; Hermansson K; Schnee J M; Friedman R J {Eriksson, 2011 #148} | Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: The re-novate II randomized trial (2010) | Pathophysiology of Haemostasis and Thrombosis | Duplicate publication (no additional data) |
| Eriksson BI, Agnelli G, Cohen A, Dahl O, Mouret P, Rosencher N, et al {Eriksson, 2004 #149} | Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin | Thrombosis and Haemostasis 2004;92(2): 428–30 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, et al{Eriksson, 2003 #150} | EXPRESS Study Group, The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study | Journal of Thrombosis and Haemostasis 2003;1(12):2490–6 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, et al{Eriksson, 2002 #151} | The oral direct thrombin inhibitor ximelagatran, and its subcutaneous form melagatran, compared with enoxaparin for prophylaxis of venous thromboembolism (VTE) in total hip or total knee replacement: the EXPRESS study | Blood 2002;100(11 pt2):abstract 299 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, et al {Eriksson, 2003 #152} | Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement | Thrombosis and Haemostasis 2003;89(2):288–96 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kalebo P, et al{Eriksson, 2002 #153} | A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I, Melagatran for THRombin inhibition in Orthopaedic surgery | Thrombosis & Haemostasis 2002;87(2):231–37 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, Baur M, Lindbratt S, Bach D, Ekman S, Close P | Recombinant hirudin, CGP 39393, (TMREVASC), is more effective than enoxaparin as prophylaxis of thromboembolic complications in patients undergoing total hip replacement [Abstract] | Journal of Bone and Joint Surgery British 1997;79-B(Suppl 1):95–6 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, BaurM, Ekman S, Lindbratt S, Bach D, Kalebo P, et al {Eriksson, 1997 #154} | Recombinant hirudin, desirudin (TMREVASC), is more effective than enoxaparin as prophylaxis of thromboembolic complications in patients undergoing total hip replacement | Thrombosis and Haemostasis 1997;564 (Supplement June):Abstract No PD-2309 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, et al{Eriksson, 2002 #155} | Melagatran for Thrombin, inhibition in Orthopaedic Surgery, Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomized trial | Lancet 2002;360(9344): 1441–47 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, Borris LC, Friedman RJ, et al {Eriksson, 2008 #156} | Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty | N Engl J Med 2008; 358(26):2765–2775 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, Dahl OE, Ahnfelt L, Kälebo P, Stangier J, Nehmiz G, et al {Eriksson, 2004 #157} | Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I | J Thromb Haemost 2004;2:1573–80 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, Dahl OE, van Dijk CN, Frostick SP, Kurth AA, Rosencher N, et al {Eriksson, 2006 #158} | A new oral aniticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery (The RE-MODEL Trial) | Blood 2006;108:173 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, et al {Eriksson, 2007 #159} | A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery | J Thromb Haemost 5 (8) (2007) 1660–1665 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, et al {Eriksson, 2006 #160} | A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement | Circulation 114 (22) (2006) 2374–2381 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, et al {Eriksson, 2007 #161} | Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolismin patients undergoing total hip replacement | Thromb Res 120 (5) (2007) 685–693 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, et al {Eriksson, 2006 #162} | Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement | J Thromb Haemost 4 (1) (2006) 121–128 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, Lindbratt S, Kalebo P{Eriksson, 2000 #163} | Methro II: dose-response study of the novel oral, direct thrombin randomize, H 376/95 and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip knee replacement | Haemostasis 2000;30(Suppl 1):20–1 | Pre-2010 (presumably excluded by Uconn) | |
| Eriksson BI, Wille-Jorgensen P, Kalebo P, et al {Eriksson, 1997 #164} | A comparison of recombinant hirudin with a low-molecularweight heparin to prevent thromboembolic complications after total hip replacement | Journal of Vascular and Interventional Radiology 1998;9(3):530 | Duplicate publication (no additional data) | |
| 22315265 | Falck-Ytter Y and Francis CW and Johanson NA and Curley C and Dahl OE and Schulman S and Ortel TL and Pauker SG and Colwell CW Jr {Falck-Ytter, 2012 #60} | Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | Duplicate publication (no additional data) | |
| 15950853 | Farag E, Dilger J, Brooks P, et al {Farag, 2005 #99} | Epidural analgesia improves early rehabilitation after total knee replacement | J Clin Anesth 2005;17:281–5 | No intervention of interest |
| Abstract OC681 | Fisher W; Agnelli G; George D; Kakkar A k; Lassen M r; Mismetti P; Mouret P; Bregeault M F; Turpie A G G {Fisher, 2009 #165} | Extended venous thromboembolism (VTE) prophylaxis after hip fracture surgery with the ultra-low-molecular-weight heparin (ULMWH) semuloparin (2010) | Pathophysiology of Haemostasis and Thrombosis | Duplicate publication (no additional data) |
| Abstract P330 | Fisher W; Agnelli G; George D; Kakkar A; Lassen M R; Mismetti P; Mouret P; Destree D; Turpie A G G | The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after hip fracture surgery (2010) | Pathophysiology of Haemostasis and Thrombosis | Duplicate publication (no additional data) |
| Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al {Francis, 2003 #166} | EXULT A Study Group, Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement | New England Journal of Medicine 2003;349 (18):1703–12 | Pre-2010 (presumably excluded by Uconn) | |
| Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al | Randomized, doubleblind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR) | Journal of Thrombosis and Haemostasis 2003;1(Suppl 1):Abstract P1912 | Pre-2010 (presumably excluded by Uconn) | |
| Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement GD, et al {Francis, 2002 #167} | Randomized, doubleblind, comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR) | Blood 2002;100 (11 pt 2):Abstract 300 | Pre-2010 (presumably excluded by Uconn) | |
| Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, et al {Francis, 2001 #168} | Randomized doubleblind, comparative study of ximelagatran (pINN, formerly H 376/95), an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee arthroplasty (TKA) | Thrombosis and Haemostasis 2001;July Suppl:Abstract OC44 | Pre-2010 (presumably excluded by Uconn) | |
| Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, et al {Francis, 2002 #169} | Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty, A randomized, double-blind trial | Annals of Internal Medicine 2002;137(8):648–55 | Pre-2010 (presumably excluded by Uconn) | |
| Fredin H, Bergqvist D, Cederholm C, Lindblad B, Nyman U {Fredin, 1989 #170} | Thromboprophylaxis in hip arthroplasty, Dextran with graded compression or preoperative dextran compared in 150 patients | Acta Orthopaedica Scandinavica 1989;60(6): 678–81 | Pre-2010 (presumably excluded by Uconn) | |
| 18534456 | Froimson MI, Murray TG, Fazekas AF {Froimson, 2009 #94} | Venous thromboembolic disease reduction with a portable pneumatic compression device | J Arthroplasty 2009;24:310–6 | Combined TKR and THR |
| Fuji T, Fujita S, Ochi T {Fuji, 2008 #171} | Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients | Int Orthop 2008;32(4):443–451 | Pre-2010 (presumably excluded by Uconn) | |
| Fuji T, Wang C, Fujita S, Tachibana S, Kawai Y, Koretsune Y, et al {Fuji, 2010 #172} | Edoxaban versus enoxaparin for thromboprophylaxis after total knee replacement: the STARS E-3 trial | Presented at 21st International Congress on Thrombosis, Milan, Italy, 6–9 July 2010 | Duplicate publication (no additional data) | |
| Fuji T, Wang CJ, Fujita S, Tachibana S, Kawai Y {Fuji, 2009 #173} | Edoxaban in patients undergoing total hip arthroplasty: a phase Iib dose-finding study [Abstract] | Proceedings of the Annual Meeting of the American Society of Hematology, New Orleans, Louisiana, 5–8 December 2009, Abstract 2098 | Pre-2010 (presumably excluded by Uconn) | |
| EMBASE 71208004 | Fuji T; Fujita S; Abe Y; Tachibana S; Kawai Y {Fuji, 2013 #174} | Evaluation of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery (2013) | Journal of thrombosis and haemostasis : JTH, 2013, 11, 556 | Combined TKR and THR |
| Poster 3320 | Fuji T; Fujita S; Tachibana S; Kawai Y; Koretsune Y; Yamashita T; Nakamura M {Fuji, 2010 #175} | Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial (2010) | Blood. Conference: 52nd Annual Meeting of the American Society of Hematology, ASH | Duplicate publication (no additional data) |
| 25653574 | Fuji T1, Fujita S2, Kawai Y3, Abe Y4, Kimura T5, Fukuzawa M6, Abe K7, Tachibana S8. {Fuji, 2015 #8} | A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery | Thromb J. 2015 Jan 30;13(1):6 | No comparison of interest |
| Fujisawa M, Naito M, Asayama I, Kambe T, Koga K{Fujisawa, 2003 #176} | Effect of calf-thigh intermittent pneumatic compression device after total hip arthroplasty: Comparative analysis with plantar compression on the effectiveness of reducing thrombogenesis and leg swelling | Journal of Orthopaedic Science 2003;8(6):807–11 | Pre-2010 (presumably excluded by Uconn) | |
| Abstract P366 | Fujita S; Fuji T; Tachibana S; Nakamura M; Kawai Y | Safety and efficacy of edoxaban in patients undergoing hip fracture surgery (2010) | Pathophysiology of Haemostasis and Thrombosis | Duplicate publication (no additional data) |
| 19684153 | Gandhi R, Razak F, Tso P, et al {Gandhi, 2009 #91} | Metabolic syndrome and the incidence of symptomatic deep vein thrombosis following total knee arthroplasty | J Rheumatol 2009;36:2298–301 | No intervention of interest |
| 22177437 | Ge YY and Cheng JQ and Xi WJ and Xu Y and Kang YM {Ge, 2011 #66} | [Effects of ulinastatin on coagulation function and deep vein thrombosis in patients undergoing hip joint replacement]. | No intervention of interest | |
| Gent M, Hirsh J, Ginsberg JS, et al {Gent, 1996 #178} | Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after urgery for hip fracture | Circulation 1996; 93(1):80–84 | Pre-2010 (presumably excluded by Uconn) | |
| 20545808 | Gerkens S; Crott R; Closon M C; Horsmans Y; Beguin C {Gerkens, 2010 #84} | Comparing the quality of care across Belgian hospitals from medical basic datasets: the case of thromboembolism prophylaxis after major orthopaedic surgery (2010) | J Eval Clin Pract | Combined TKR and THR |
| 23142450 | Gesell MW and Gonzalez Della Valle A and Bartolome Garcia S and Memtsoudis SG and Ma Y and Haas SB and Salvati EA {Gesell, 2013 #47} | Safety and efficacy of multimodal thromboprophylaxis following total knee arthroplasty: a comparative study of preferential aspirin vs. routine randomiz chemoprophylaxis. | J Arthroplasty 2013 Apr;28(4):575–9 | Comparator mixed interventions |
| 22814857 | Gillette BP and DeSimone LJ and Trousdale RT and Pagnano MW and Sierra RJ {Gillette, 2013 #53} | Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. | Clin Orthop Relat Res 2013;471:150–4 | Combined TKR and THR |
| Glynn O {Glynn, 2002 #179} | The express study: preliminary results | International Journal of Clinical Practice 2003;57(1):57–9 | Pre-2010 (presumably excluded by Uconn) | |
| 22700784 | Gomez-Outes A and Terleira-Fernandez AI and Suarez-Gea ML and Vargas-Castrillon E {Gomez-Outes, 2012 #54} | Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. | Duplicate publication (no additional data) | |
| Gomez-Outes A; Terleira-Fernandez A; Suarez-Gea M L; Vargas-Castrillon E | New oral anticoagulants for thromboprophylaxis after total hip or knee replacement: A meta-analysis and indirect treatment comparisons (2011) | Basic and Clinical Pharmacology and Toxicology | SR or MA without references (conference abstract) | |
| 26194908 | Granero J; Diaz de Rada P; Lozano L M; Martinez J; Herrera A {Granero, 2016 #3} | Rivaroxaban versus standard of care in venous thromboembolism prevention following hip or knee arthroplasty in daily clinical practice (Spanish data from the international study XAMOS) (2015) | Revista espanola de cirugia ortopedica y traumatologia | Combined TKR and THR |
| 21870978 | Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L {Granger, 2011 #70} | Apixaban versus warfarin in patients with atrial fibrillation | N Engl J Med 2011;365: 981e992 | Not population of interest |
| noPMID 07 | Haas S; Turpie A G; Jamal W; Schmidt A; Lassen M; Mantovani L; Kreutz R | XAMOS: A non-interventional study in 17,701 patients undergoing major hip or knee surgery and receiving oral rivaroxaban or conventional regimens for thromboprophylaxis (2013) | Hamostaseologie | Duplicate publication (no additional data) |
| 1447236 | Haas SB, Tribus CB, Insall JN, et al{Haas, 1992 #113} | The significance of calf thrombi after total knee arthroplasty | J Bone Joint Surg Br 1992;74:799–802 | No comparison of interest |
| 23768996 | Hamidi V and Ringerike T and Hagen G and Reikvam A and Klemp M{Hamidi, 2013 #34} | New anticoagulants as thromboprophylaxis after total hip or knee replacement. | Duplicate publication (no additional data) | |
| 22480528 | Hamilton SC, Whang WW, Anderson BJ, Bradbury TL, Erens GA, Roberson JR{Hamilton, 2012 #57} | Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study | J Arthroplasty 2012 Oct;27(9):1594–8 | Combined TKR and THR |
| 25224874 | Hamilton W G; Reeves J D; Fricka K B; Goyal N; Engh G A; Parks N L{Hamilton, 2015 #11} | Mechanical thromboembolic prophylaxis with risk stratification in total knee arthroplasty (2015) | J Arthroplasty | No comparison of interest |
| 18034323 | Happe LE, Farrelly EM, Stanford RH, et al{Happe, 2008 #97} | Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries | J Thromb Thrombolysis 2008;26:125–31 | Combined TKR and THR |
| 23344716 | Harenberg J; Weiss C; Marx S; Zolfaghari S{Harenberg, 2013 #42} | Clinical trials with new direct oral anticoagulants: Additive value of indirect comparisons also named network meta-analyses (2013) | Phlebologie | No primary data |
| Harms M, Engstrom B {Harms, 1991 #180} | Continuous passive motion as an adjunct to treatment in the physiotherapy management of the total knee arthroplasty patient | Physiotherapy 1991;77 (4):301–7 | Pre-2010 (presumably excluded by Uconn) | |
| Harris WH, Athanasoulis CA, Waltman AC, Salzman EW {Harris, 1982 #181} | High and low-dose aspirin prophylaxis against venous thromboembolic disease in total hip replacement | J Bone Joint Surg Am 1982;64(1):63–66 | Pre-2010 (presumably excluded by Uconn) | |
| Hauer W, Sinz G, Hiesser H | Hirudin versus enoxaparin as prophylaxis of venous thromboembolism in patients undergoing total hip replacement | Annals of Hematology 1997;74(Suppl 2):A 130 | Pre-2010 (presumably excluded by Uconn) | |
| HTA-32011001330 | Hayes; Inc | Pneumatic compression for prevention of deep vein thrombosis following hip surgery (Structured abstract) (2011) | http://www | No abstract or full text available |
| EMBASE 71208848 | Heckmann M B; Hillebrand I; Silay H; Thermann H; Siebold R; Klonz A; Gruber G; Scheller G; Heckmann F {Heckmann, 2013 #182} | Rivaroxaban superior to Nadroparin for thromboprophylaxis in patients receiving hip or knee arthroplasty (2013) | Journal of thrombosis and haemostasis : JTH, 2013, 11, 822 | Combined TKR and THR |
| 26194889 | Heckmann, M., Thermann, H., Heckmann, F. {Heckmann, 2015 #254} | Rivaroxaban versus high dose nadroparin for thromboprophylaxis after hip or knee arthroplasty | Hamostaseologie | Could not retrieve |
| Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, et al, Astrazeneca Arthroplasty Study Group {Heit, 2001 #183} | Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: A phase 2 dose-finding study | Archives of Internal Medicine 2001;161 (18):2215–21 | Pre-2010 (presumably excluded by Uconn) | |
| Hoek JA, Nurmohamed MT, Hamelynck KJ, et al {Hoek, 1992 #184} | Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid | Thromb Haemost 1992; 67: 28–32 | Pre-2010 (presumably excluded by Uconn) | |
| doi: 10.1097/BCO.0000000000000222 | Holden, D. N., Maceira, E. | Thromboembolism prophylaxis failure rates after hip and knee arthroplasty: Comparison of aspirin and anticoagulants | Current Orthopaedic Practice | Combined hip and knee; NRCS N<750 |
| 25972699 | Hossain Shahcheraghi G; Javid M; Arasteh M M {Hossain Shahcheraghi, 2015 #5} | Thromboembolic disease after knee arthroplasty is rare in Southern Iran (2015) | J Orthop | nRCS N<750 |
| Howard A, Zaccagnini D, Ellis M, Williams A, Davies AH, Greenhalgh RM {Howard, 2004 #185} | Randomized clinical trial of low molecular weight heparin with thigh-length or knee-length antiembolism stockings for patients undergoing surgery | British Journal of Surgery 2004;91(7):842–7 | Pre-2010 (presumably excluded by Uconn) | |
| 19567860 | Hu S, Zhang Z-, Hua Y-, et al {Hu, 2009 #92} | A comparison of regional and general anaesthesia for total replacement of the hip or knee: A meta-analysis | Journal of Bone and Joint Surgery – Series B 2009;91:935–42 | No comparison of interest |
| Huang D, Peng Y, Su P, Ye W, Liang A {Huang, 2003 #186} | The effect of continuous passive motion after total knee arthroplasty on joint function | Chinese Journal of Clinical Rehabilitation 2003;7:1661–2 | Pre-2010 (presumably excluded by Uconn) | |
| 26182982 | Huang, R., Buckley, P. S., Scott, B., Parvizi, J., Purtill, J. J. | Administration of Aspirin as a Prophylaxis Agent Against Venous Thromboembolism Results in Lower Incidence of Periprosthetic Joint Infection | J Arthroplasty | Does not report hip and knee separately |
| Hui AC, Heras-Palou C, Dunn I, Triffitt PD, Crozier A, Imeson J, et al {Hui, 1996 #188} | Graded compression stockings for prevention of deep-vein thrombosis after hip and knee replacement | The Journal of Bone and Joint Surgery, British Volume 1996;78(4):550–4 | Pre-2010 (presumably excluded by Uconn) | |
| Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, et al{Hull, 2000 #189} | Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a doubleblind, randomized comparison, North American Fragmin Trial Investigators | Arch Intern Med 2000;160:2208–15 | Pre-2010 (presumably excluded by Uconn) | |
| noPMID 04 | Huo M H; Spencer D L; Borah B J; Mills R M; Fan Y; Yarlas A; Klaskala W {Huo, 2012 #190} | Post-discharge venous thromboembolism and bleeding in a large cohort of patients undergoing total hip or total knee arthroplasty (2012) | Journal of Clinical Outcomes Management | No intervention of interest |
| Abstract PCV4 | Huo M H; Spencer D L; Fan Y; Borah B J; Mills R M; Klaskala W {Huo, 2012 #191} | Thromboprophylaxis and the risk of post-discharge venous thromboembolism and bleeding in patients undergoing total hip or knee arthroplasty (2012) | Value in Health | No intervention of interest |
| Abstract 0564 | Huo M; Eriksson B; Dahl O; Kurth A; Hantel S; Hermansson K; Schnee J; Friedman R {Huo, 2010 #192} | Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: The re-novate II randomized trial (2010) | Haematologica | Duplicate publication (no additional data) |
| 21621959 | IJRCW Committee{, 2012 #75} | A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty | J Arthroplasty 2012;27:1–9e2 | nRCS N<750 |
| 21621959 | Intermountain Joint Replacement Center Writing Committee. | A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty. | J Arthroplasty 2012;27(1):1. | nRCS N<750 |
| 25877506 | Izumi, M., Migita, K., Nakamura, M., Jiuchi, Y., Sakai, T., Yamaguchi, T., Asahara, T., Nishino, Y., Bito, S., Miyata, S., Kumagai, K., Osaki, M., Mawatari, M., Motokawa, S. {Izumi, 2015 #258} | Risk of venous thromboembolism after total knee arthroplasty in patients with rheumatoid arthritis | J Rheumatol | no medication as control |
| 22832942 | Jameson SS and Rymaszewska M and Hui AC and James P and Serrano-Pedraza I and Muller SD{Jameson, 2012 #52} | Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. | Combined TKR and THR | |
| 22253396 | Januel JM and Chen G and Ruffieux C and Quan H and Douketis JD and Crowther MA and Colin C and Ghali WA and Burnand B{Januel, 2012 #62} | Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. | Duplicate publication (no additional data) | |
| 21196550 | Jensen CD and Steval A and Partington PF and Reed MR and Muller SD{Jensen, 2011 #80} | Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. | nRCS N<750 | |
| 22148001 | Ji HM and Lee YK and Ha YC and Kim KC and Koo KH{Ji, 2011 #67} | Little impact of antiplatelet agents on venous thromboembolism after hip fracture surgery. | No intervention of interest | |
| 27213284 | Jiang, L., Zhang, S., Zhao, Y. {Jiang, 2016 #248} | Stacked Modalities’ Thromboprophylactic Therapy for Patients Undergoing Total Knee Replacement Surgery | J Knee Surg | Could not retrieve |
| Johnson DP, Eastwood DM {Johnson, 1992 #193} | Beneficial effects of continuous passive motion after total condylar knee arthroplasty | Annals of the Royal College of Surgeons of England 1992;74(6): 412–6 | Pre-2010 (presumably excluded by Uconn) | |
| 24334158 | Jorgensen CC and Jacobsen MK and Soeballe K and Hansen TB and Husted H and Kjaersgaard-Andersen P and Hansen LT and Laursen MB and Kehlet H {Jorgensen, 2013 #23} | Thromboprophylaxis only during randomized ion in fast-track hip and knee arthroplasty, a prospective cohort study. | Combined TKR and THR | |
| 1997063 | Jorgensen LN, Rasmussen LS, Nielsen PT, et al {Jorgensen, 1991 #116} | Antithrombotic efficacy of continuous extradural analgesia after knee replacement | Br J Anaesth 1991;66:8–12 | No intervention of interest |
| 8384388 | Jorgensen PS, Knudsen JB, Broeng L, et al {Jorgensen, 1993 #112} | [The thromboprophylactic effect of low molecular weight heparin (Fragmin) in hip fracture surgery. A placebo controlled trial] | Ugeskr Laeger 1993;155:706–8 | Duplicate publication (no additional data) |
| Josefsson G, Dahlqvist A, Bodfors B {Josefsson, 1987 #194} | Prevention of thromboembolism in total hip replacement: Aspirin versus dihydroergotamine-heparin | Acta Orthop Scand 1987;58(6):626–629 | Pre-2010 (presumably excluded by Uconn) | |
| Kakkar AK, Brenner B, Dahl OE, et al {Kakkar, 2008 #195} | Extended duration rivaroxaban versus shortterm enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial | Lancet 2008; 372(9632):31–39 | Pre-2010 (presumably excluded by Uconn) | |
| Kakkar VV, Howes J, Sharma V, Kadziola Z {Kakkar, 2000 #196} | A comparative double-blind, randomized trial of a new second generation LMWH (bemiparin) and UFH in the prevention of postoperative venous thromboembolism, The Bemiparin assessment group | Thromb Haemost 2000;83(4):523–529 | Pre-2010 (presumably excluded by Uconn) | |
| Kalodiki E, Gill K, Al-Kutobi, Birch R, Harris N, Hunt D, et al {Kalodiki, 1992 #197} | Low molecular weight heparin with or without graduated elastic compression in deep vein prophylaxis after elective hip replacement | British Journal of Surgery 1992; Vol 79, issue 11:1223 | Pre-2010 (presumably excluded by Uconn) | |
| Kalodiki E, Nicolaides A, Al-Kutoubi A, Birch B, Harris N, Hunt D, et al {Kalodiki, 1993 #198} | Low molecular weight heparin (LMWH) and LMWH plus graduated elastic compression for deep venous thrombosis (DVT) prophylaxis in total hip replacement | Thrombosis and Haemostasis 1993; Vol 69, issue 6:650– Abstract No 387 | Pre-2010 (presumably excluded by Uconn) | |
| Kalodiki E, Nicolaides AN, Al-Kutoubi A, Birch R, Harris N, Hunt D, et al {Kalodiki, 1993 #199} | LMWH and LMWH plus graduated elastic compression for DVT prophylaxis in total hip replacement | Thrombosis and Haemostasis 1993; Vol 69, issue 6:619–Abstract No 270 | Pre-2010 (presumably excluded by Uconn) | |
| Kanan PS, Schwartsmann CR, Boschin LC, Conrad S, Silva MF{Kanan, 2008 #200} | Estudo randomized entre rivaroxaban e enoxaparina na profilaxia de tromboembolismo venoso profundo em pacientes submetidos à artroplastia total do quadril | Rev Bras Ortop 2008;43(8):319–28 | Pre-2010 (presumably excluded by Uconn) | |
| 21748508 | Kang BJ and Lee YK and Kim HJ and Ha YC and Koo KH{Kang, 2011 #72} | Deep venous thrombosis and pulmonary embolism are uncommon in East Asian patients after total hip arthroplasty. | No comparison of interest | |
| 26630467 | Kaye, I. D., Patel, D. N., Strauss, E. J., Alaia, M. J., Garofolo, G., Martinez, A., Jazrawi, L. M. {Kaye, 2013 #251} | Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial | Bull Hosp Jt Dis (2013) | Placebo trial |
| 22858314 | Khokhar A and Chari A and Murray D and McNally M and Pandit H{Khokhar, 2013 #51} | Venous thromboembolism and its prophylaxis in elective knee arthroplasty: an international perspective. | Duplicate publication (no additional data) | |
| 23683524 | Kim G H; Park B Y; Bae T Y; Kang J W; In Y{Kim, 2013 #36} | Can enoxaparin reduce thromboembolism related events after primary TKA in rando patients? (2013) | Journal of Arthroplasty | nRCS placebo comparison |
| 12892186 | Kim YH, Oh SH, Kim JS{Kim, 2003 #100} | Incidence and natural history of deep-vein thrombosis after total hip arthroplasty. A prospective and randomized clinical study | J Bone Joint Surg Br 2003;85:661–5 | No intervention of interest |
| Abstract PII6 | Kreutz R; Schmidt A; Turpie A G; Lassen M R; Mantovani L G; Holberg G; Haas S {Kreutz, 2013 #201} | Rivaroxaban or conventional thromboprophylaxis in routine clinical practice in over 17,000 patients undergoing major orthopedic surgery: Impact of co-medications on adverse events (2013) | Clinical Pharmacology and Therapeutics | Duplicate publication (no additional data) |
| 26580706 | Kreutz, R., Haas, S., Holberg, G., Lassen, M. R., Mantovani, L. G., Schmidt, A., Turpie, A. G. G. {Kreutz, 2016 #252} | Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: Co-medication interactions | British Journal of Clinical Pharmacology | Does not report hip and knee separately |
| 21575551 | Kucera T and Maly R and Urban K and Sponer P {Kucera, 2011 #77} | [Venous thromboembolism prophylaxis after total hip arthroplasty]. | Acta Chir Orthop Traumatol Cech. 2011;78(2):101–5. | nRCS N<750 |
| 23796558 | Kulshrestha V and Kumar S {Kulshrestha, 2013 #33} | DVT prophylaxis after TKA: routine anticoagulation vs risk screening approach – a randomized study. | nRCS N<750 | |
| noPMID 11 | Kumar S L V; Rao A S | Prospective study of commonly used prophylactic anticoagulants in arthroplasy patients (2012) | Malaysian Orthopaedic Journal | Combined TKR and THR |
| Kurth AA, Dahl OE, van-Dijk CN, Eriksson BI, Frostick SP, Rosencher N, et al {Kurth, 2009 #202} | A new oral anticoagulant, dabigatran etexilate, is effective and safe for the prevention of venous thromboembolism after total knee replacement | The Journal of Bone and Joint Surgery 2009;91-B(SUPP I):7b | Pre-2010 (presumably excluded by Uconn) | |
| 23519234 | Kwok CS and Pradhan S and Yeong JK and Loke YK {Kwok, 2013 #39} | Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison. | Duplicate publication (no additional data) | |
| 22220855 | Kwong {Kwong, 2012 #63} | Thromboprophylaxis, bleeding and post-operative prosthetic joint infection in total hip and knee arthroplasty: a comprehensive literature review. | Expert Opin Pharmacother | No primary data |
| 23387806 | Lalmohamed A and Vestergaard P and Jansen PA and Grove EL and de Boer A and Leufkens HG and van Staa TP and de Vries F {Lalmohamed, 2013 #40} | Prolonged outpatient vitamin K antagonist use and risk of venous thromboembolism in patients undergoing total hip or knee replacement. | No analysis by intevention | |
| Lalmohamed A; Vestergaard P; Klop C; Bazelier M; De Boer A; De Vries F | Risk of venous thromboembolism in patients with total hip/knee replacements and matched controls: A population-based cohort study in Denmark (2012) | Osteoporosis International | Duplicate publication (no additional data) | |
| Abstract PP400 | Lalmohamed A; Vestergaard P; Pouwels S; Klop C; De Boer A; De Vries F {Lalmohamed, 2012 #203} | Risk of venous thromboembolism in patients with total hip/knee replacements and matched controls: A population-based cohort study in Denmark (2012) | Bone | No analysis by intevention |
| 24965841 | Laporte S and Chapelle C and Bertoletti L and Lega JC and Cucherat M and Zufferey PJ and Darmon JY and Mismetti P {Laporte, 2014 #15} | Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs. | Duplicate publication (no additional data) | |
| Abstract OC331 | Lassen M R; Agnelli G; Fisher W; George D; Kakkar A; Mismetti P; Mouret P; Lawson F; Turpie A G G | The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after elective knee replacement surgery (2010) | Pathophysiology of Haemostasis and Thrombosis | Duplicate publication (no additional data) |
| Abstract OC356 | Lassen M R; Gallus A; Raskob G E; Pineo G; Chen D; Ramirez L M {Lassen, 2010 #204} | Randomized double-blind comparison of apixaban and enoxaparin for thromboprophylaxis after hip replacement: The advance-3 trial (2010) | Pathophysiology of Haemostasis and Thrombosis | Duplicate publication (no additional data) |
| Lassen MR, Ageno W, Borris LC, et al {Lassen, 2008 #205} | Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty | N Engl J Med 2008; 358(26):2776–2786 | Pre-2010 (presumably excluded by Uconn) | |
| Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejø Bro HP, Andersen G, et al {Lassen, 1998 #206} | Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty—the Danish Prolonged Prophylaxis (DaPP) Study | Thromb Res 1998;89:281–7 | Pre-2010 (presumably excluded by Uconn) | |
| Lassen MR, Dahl OE, Mismetti P, Destree D, Turpie AG {Lassen, 2009 #207} | AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery—TREK: a dose-ranging study | J Thromb Haemost 2009;7(4):566–572 | Pre-2010 (presumably excluded by Uconn) | |
| Lassen MR, Davidson BL, Gallus A, Pineo A, Ansell J, Deitchman D{Lassen, 2003 #208} | A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery—on behalf of the razaxaban investigators [Abstract] | Blood 2003;102(11 Pt 1):15a | Pre-2010 (presumably excluded by Uconn) | |
| Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ {Lassen, 2009 #209} | Apixaban or enoxaparin for thromboprophylaxis after knee replacement | N Engl J Med 2009; 361(6):594–604 | Pre-2010 (presumably excluded by Uconn) | |
| 8666626 | Laupacis A, Rorabeck C, Bourne R, et al {Laupacis, 1996 #109} | The frequency of venous thrombosis in cemented and non-cemented hip arthroplasty | J Bone Joint Surg Br 1996;78:210–2 | No intervention of interest |
| 25069387 | Lazo-Langner A and Fleet JL and McArthur E and Garg AX {Lazo-Langner, 2014 #13} | Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study. | Combined TKR and THR | |
| NoPMID 09 | Lazo-Langner A; Fleet J L; McArthur E; Garg A X {Lazo-Langner, 2013 #210} | Rivaroxaban versus low molecular weight heparin for the prevention of venous thromboembolism after orthopedic surgery: A population-based study (2013) | Blood. Conference: 55th Annual Meeting of the American Society of Hematology, ASH | No comparison of interest |
| Leclerc JR, GeertsWH, Desjardins L, et al {Leclerc, 1992 #211} | Prevention of deep vein thrombosis after major knee surgery—a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo | Thromb Haemost 1992;67(4):417–423 | Pre-2010 (presumably excluded by Uconn) | |
| 22066704 | Lee C H; Cheng C L; Chang C H; Kao Yang Y H; Lin L J; Lin T C; Yang C Y {Lee, 2012 #69} | Universal pharmacological thromboprophylaxis for total knee arthroplasty may not be necessary in low-risk populations: A nationwide study in Taiwan (2012) | Journal of Thrombosis and Haemostasis | No comparison of interest |
| 23052111 | Lee SH and Cho KY and Khurana S and Kim KI {Lee, 2013 #49} | Less blood loss under concomitant administration of tranexamic acid and indirect factor Xa inhibitor following total knee arthroplasty: a prospective randomized controlled trial. | No intervention of interest | |
| 23112075 | Leegwater NC and Willems JH and Brohet R and Nolte PA {Leegwater, 2012 #48} | Cryocompression therapy after elective arthroplasty of the hip. | Hip Int. 2012 Sep–Oct;22(5):527–33 | No intervention of interest |
| 1516307 | Lemos MJ, Sutton D, Hozack WJ, et al {Lemos, 1992 #114} | Pulmonary embolism in total hip and knee arthroplasty. Risk factors in patients on warfarin prophylaxis and analysis of the prothrombin time as an indicator of warfarin’s prophylactic effect | Clin Orthop 1992;:158–63 | No comparison of interest |
| Lenssen TA, van Steyn MJ, Crijns YH, Waltjé EM, Roox GM, Geesink RJ, et al {Lenssen, 2008 #212} | Effectiveness of prolonged use of continuous passive motion (CPM), as an adjunct to physiotherapy, after total knee arthroplasty | BMC Musculoskeletal Disorders 2008;9:60 | Pre-2010 (presumably excluded by Uconn) | |
| 10565650 | Levy O, Martinowitz U, Oran A, et al {Levy, 1999 #103} | The use of fibrin tissue adhesive to reduce blood loss and the need for blood transfusion after total knee arthroplasty. A prospective randomized multicenter study | J Bone Joint Surg Am 1999;81:1580–8 | No intervention of interest |
| 22489519 | Li J and Wu G and Ji WF and Tong PJ {Li, 2012 #56} | [Case-control study on ultra-early application with intermittent pneumatic compression to prevent postoperative deep venous thrombosis of intertrochanteric femoral fracture in elderly patients]. | Zhongguo Gu Shang. 2012 Jan;25(1):32–4. | nRCS N<750 |
| 9070518 | Lieberman JR, Wollaeger J, Dorey F, et al {Lieberman, 1997 #106} | The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty | J Bone Joint Surg Am 1997;79:319–25 | No comparison of interest |
| 24154580 | Low MH, Yeo SJ, Chin PL, et al. {Low, 2013 #260} | A Singapore perspective on the use of a short course of chemothromboprophylaxis in patients who underwent total knee arthroplasty. | Singapore Med J 2013;54(10):560. | NRCS N<750 |
| Lynch AF, Bourne RB, Rorabeck CH, Rankin RN, Donald A {Lynch, 1988 #213} | Deep-vein thrombosis and continuous passive motion after total knee arthroplasty | The Journal of Bone and Joint Surgery, American Volume 1988;70(1):11–4 | Pre-2010 (presumably excluded by Uconn) | |
| 27143213 | Malhotra, R., Babhulkar, S., Sanjib, K. B., Clemens, A., Dadi, A., Iyer, R., Kamath, S., Mody, B., Mutha, S., Reddy, G., Shah, V., Shetty, N., Tapasvi, S., Wadhwa, M. {Malhotra, 2016 #249} | Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study | Asian J Surg | Subpopulation not of specific interest |
| Mantha S{Mantha, 2011 #214} | Oral factor Xa inhibitors vs. enoxaparin for thromboprophylaxis after joint replacement surgery: A meta-analysis (2011) | Journal of Thrombosis and Haemostasis | SR or MA without references (conference abstract) | |
| 26520693 | Mao, Y. C., Chen, S. T., Chen, C. H., Hsieh, K. P., Gan, K. H. {Mao, 2015 #253} | Rivaroxaban in preventing venous thromboembolism after arthroplastic surgery in Taiwan | Kaohsiung Journal of Medical Sciences | Does not report hip and knee separately |
| McInnes J, Larson MG, Daltroy LH, Brown T, Fossel AH, Eaton HM, et al {Mclnnes, 1992 #215} | A controlled evaluation of continuous passive motion in patients undergoing total knee arthroplasty | JAMA 1992;268(11):1423–8 | Pre-2010 (presumably excluded by Uconn) | |
| 4027101 | McKenzie PJ, Wishart HY, Gray I, et al {McKenzie, 1985 #118} | Effects of anaesthetic technique on deep vein thrombosis. A comparison of subarachnoid and general anaesthesia | Br J Anaesth 1985;57:853–7 | No intervention of interest |
| 19968601 | McNamara I, Sharma A, Prevost T, et al {McNamara, 2009 #90} | Symptomatic venous thromboembolism following a hip fracture | Acta Orthop 2009;80:687–92 | No comparison of interest |
| 20424181 | Melillo S N; Scanlon J V; Exter B P; Steinberg M; Jarvis C I{Melillo, 2010 #86} | Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery (2010) | Ann Pharmacother | Duplicate publication (no additional data) |
| 21305339 | Merli G J; Malangone E; Lin J; Lamerato L; Stern L{Merli, 2011 #78} | Real-world practices to prevent venous thromboembolism with pharmacological prophylaxis in US orthopedic surgery patients: An analysis of an integrated healthcare database (2011) | Journal of Thrombosis and Thrombolysis | No outcome of interest |
| 25047862 | Migita K and Bito S and Nakamura M and Miyata S and Saito M and Kakizaki H and Nakayama Y and Matsusita T and Furuichi I and Sasazaki Y and Tanaka T and Yoshida M and Kaneko H and Abe I and Mine T and Ihara K and Kuratsu S and Saisho K and Miyahara H and Segata T and Nakagawa Y and Kamei M and Torigoshi T and Motokawa S{Migita, 2014 #14} | Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study. | nRCS N<750 | |
| Abstract O-TU-023 | Migita K; Miyata S; Bito S; Nakamura M; Saito M; Nakayama Y; Akimoto H; Matsushita T; Yamada S; Furuichi I; Sasazaki Y; Tanaka T; Yoshida M; Kaneko H; Abe I; Mine T; Ihara K; Kuratsu S; Kamei M; Motokawa S {Migita, 2011 #216} | Seroconversion of anti-PF4/heparin antibodies and its association with deep vein thrombosis in orthopedic surgery patients receiving various thromboprophylaxis methods (2011) | Journal of Thrombosis and Haemostasis | nRCS N<750 |
| 1864027 | Mitchell D, Friedman RJ, Baker JD,3rd, et al {Mitchell, 1991 #115} | Prevention of thromboembolic disease following total knee arthroplasty. Epidural versus general anesthesia | Clin Orthop 1991;(269):109–12 | No intervention of interest |
| 7324741 | Modig J, Hjelmstedt A, Sahlstedt B, et al {Modig, 1981 #119} | Comparative influences of epidural and general anaesthesia on deep venous thrombosis and pulmonary embolism after total hip replacement | Acta Chir Scand 1981;147:125–30 | No intervention of interest |
| 22134209 | Mont MA and Jacobs JJ and Boggio LN and Bozic KJ and Della Valle CJ and Goodman SB and Lewis CG and Yates AJ Jr and Watters WC 3rd and Turkelson CM and Wies JL and Donnelly P and Patel N and Sluka P {Mont, 2011 #68} | Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. | Duplicate publication (no additional data) | |
| Montgomery F, Eliasson M {Montgomery, 1996 #217} | Continuous passive motion compared to active physical therapy after knee arthroplasty: similar hospitalization times in a randomized study of 68 patients | Acta Orthopaedica Scandinavica 1996;67(1):7–9 | Pre-2010 (presumably excluded by Uconn) | |
| Mouret P, Eriksson B, Wille-Jorgensen P, Kalebo P, Rosencher N, Bosch P, et al | A comparison of recombination hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement | Annals of Hematology 1998;76(Suppl I):A 11 | Duplicate publication (no additional data) | |
| Abstract OC316 | Mouret P; Agnelli G; Fisher W; George D; Kakkar A; Lassen M R; Mismetti P; Lawson F; Turpie A G G | The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after elective hip replacement surgery (2010) | Pathophysiology of Haemostasis and Thrombosis | Duplicate publication (no additional data) |
| Abstract MO2 | Munakata J; Li H; Luo R; Guo Y; O’Sullivan A; Duran A; Nelson M {Munakata, 2013 #218} | Use of real-world evidence (RWE) to validate a trial-based health economic model (2013) | Value in Health | Combined TKR and THR |
| 23852662 | Munoa L and Gonzalez AB and Diaz de Rada P and Valenti A and Valenti JR {Munoa, 2014 #32} | Rivaroxaban is as efficient and safe as bemiparin as thromboprophylaxis in knee arthroscopy. | Not surgery of interest | |
| 22258781 | Nagase Y and Yasunaga H and Horiguchi H and Hashimoto H and Shoda N and Kadono Y and Matsuda S and Nakamura K and Tanaka S {Nagase, 2011 #61} | Risk factors for pulmonary embolism and the effects of fondaparinux after total hip and knee arthroplasty: a retrospective observational study with use of a national database in Japan. | Combined TKR and THR | |
| 23682178 | Nair V and Kumar R and Singh BK and Sharma A and Joshi GR and Pathak K {Nair, 2013 #37} | Comparative study of extended versus short term thromboprophylaxis in patients undergoing elective total hip and knee arthroplasty in Indian population. | nRCS N<750 | |
| Navarro-Quilis A, Castellet E, Rocha E, Paz-Jimenez J, Planes A {Navarro-Quilis, 2003 #219} | Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial | J Thromb Haemost 2003;1(3):425–432 | Pre-2010 (presumably excluded by Uconn) | |
| 2186591 | Nielsen PT, Jorgensen LN, Albrecht-Beste E, et al {Nielsen, 1990 #117} | Lower thrombosis risk with epidural blockade in knee arthroplasty | Acta Orthop Scand 1990;61:29–31 | No intervention of interest |
| Norgren L, Toksvig-Larsen S, Magyar G, et al {Norgren, 1998 #220} | Prevention of deep vein thrombosis in knee arthroplasty, Preliminary results from a randomized controlled study of low molecular weight heparin vs foot pump compression | Int Angiol 1998;17:93 | Pre-2010 (presumably excluded by Uconn) | |
| 21670542 | Ogawa S, Shinohara Y, Kanmuri K {Ogawa, 2011 #74} | Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation, -The ARISTOTLE-J study- | Circ J. 2011;75(8):1852–9 | Not population of interest |
| Ohlund C, Fransson SG, Starck SA {Öhlund, 1983 #221} | Calf compression for prevention of thromboembolism following hip surgery | Acta Orthopaedica Scandinavica 1983;54(6):896–9 | Pre-2010 (presumably excluded by Uconn) | |
| Opina A; Golwala H; AbuFadel M; Tafur A{Opina, 2012 #222} | Rivaroxaban is Associated with Higher Incidence of Major Bleeding Compared to Low Molecular Weight Heparin for Venous Thromboembolism Prophylaxis-A Meta-analysis (2012) | Circulation. Conference: American Heart Association | SR or MA without references (conference abstract) | |
| 26200403 | Ozler T; Ulucay C; Onal A; Altintas F{Ozler, 2015 #2} | Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement (2015) | Acta Orthop Traumatol Turc | Combined TKR and THR |
| 24264881 | Parvizi J and Huang R and Raphael IJ and Arnold WV and Rothman RH{Parvizi, 2014 #25} | Symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors. | Combined TKR and THR | |
| 24845718 | Parvizi J and Parmar R and Raphael IJ and Restrepo C and Rothman RH{Parvizi, 2014 #16} | Proximal deep venous thrombosis and pulmonary embolus following total joint arthroplasty. | Combined TKR and THR | |
| Abstract 972 | Patorno E; Bateman B; Choudhry N; Landon J; Schneeweiss S {Patorno, 2013 #223} | Medical and mechanical prophylaxis for venous thromboembolism after total hip and knee replacement (2013) | Pharmacoepidemiology and Drug Safety | No comparison of interest |
| 23594983 | Peidro-Garces L and Otero-Fernandez R and Lozano-Lizarraga L {Peidro-Garces, 2013 #38} | [Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study]. | Combined TKR and THR | |
| Perhoniemi V, Vuorinen J, Myllynen P, et al {Perhoniemi, 1995 #224} | The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery–a comparison with the dihydroergotamine-heparin combination | Ann Chir Gynaecol 1996; 85: 359–363 | Pre-2010 (presumably excluded by Uconn) | |
| Permunian E T; Ageno W; Dentali F; Riva N {Permunian, 2015 #225} | Clinical impact of bleeding complications with direct oral anticoagulants for the prevention of venous thromboembolism in orthopaedic surgery: A systematic review and meta-analysis of randomized controlled trials (2015) | Journal of Thrombosis and Haemostasis | SR or MA without references (conference abstract) | |
| Peters F, Cohen AT, Agnelli G, Dahl OE, Eriksson BI, Kalebo P | Ximelagatran and its subcutaneous form melagatran, versus enoxaparin as thromboprophylaxis in total hip or total knee replacement | British Journal of Haematology 2003;121(Suppl 1):42 | Pre-2010 (presumably excluded by Uconn) | |
| Pietsch M, Kuhle J, Hamer H, et al {Pietsch, 2002 #226} | Mechanical versus drug prevention of thrombosis after total hip endoprosthesis implantation, A randomized, controlled clinical study | Biomed Tech (Berl) 2003;48:207 | Pre-2010 (presumably excluded by Uconn) | |
| 11792778 | Pitto RP, Hamer H, Fabiani R, et al {Pitto, 2002 #102} | Prophylaxis against fat and bone-marrow embolism during total hip arthroplasty reduces the incidence of postoperative deep-vein thrombosis: a controlled, randomized clinical trial | J Bone Joint Surg Am 2002;84-A:39–48 | No intervention of interest |
| Pitto RP, Hamer H, Heiss-Dunlop W, et al {Pitto, 2004 #227} | Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomized clinical trial | J Bone Joint Surg Br 2004;86:639 | Pre-2010 (presumably excluded by Uconn) | |
| 9042560 | Planes A, Vochelle N, Darmon JY, et al {Planes, 1996 #110} | Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomized double-blind placebo-controlled trial | Drugs 1996;52:47–54 | Not population of interest |
| 8684199 | Planes A, Vochelle N, Darmon JY, et al {Planes, 1996 #108} | Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo | Lancet 1996;348:224–8 | Not population of interest |
| Planes A, Vochelle N, Fagola M, Bellaud M {Planes, 1998 #228} | Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery, Reviparin Study Group | Blood Coagul Fibrinolysis 1998;9(6):499–505 | Pre-2010 (presumably excluded by Uconn) | |
| Planes A, Vochelle N, FagolaM, et al {Planes, 1989 #229} | Once-daily dosing of enoxaparin (a low molecular weight heparin) in prevention of deep vein thrombosis after total hip replacement | Acta Chir Scand Suppl 1990;556:108–115 | Pre-2010 (presumably excluded by Uconn) | |
| Porteous MJ, Nicholson EA, Morris LT, James R, Negus D {Porteous, 1989 #230} | Thigh length versus knee length stockings in the prevention of deep vein thrombosis | British Journal of Surgery 1989;76 (3):296–7 | Pre-2010 (presumably excluded by Uconn) | |
| 22219258 | Poultsides LA and Gonzalez Della Valle A and Memtsoudis SG and Ma Y and Roberts T and Sharrock N and Salvati E {Poultsides, 2012 #64} | Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. | Duplicate publication (no additional data) | |
| Abstract 903 | Pratt N; Graves S; Cashman K; Caughey G; Roughead E {Pratt, 2014 #231} | Anti-coagulation after hip or knee joint replacement: Assessment of the benefits and risks in an elderly cohort (2014) | Pharmacoepidemiology and Drug Safety | Insufficient results data reported |
| 25678543 | Protty, M. B., Aithal, S., Hickey, B., Rebecca, P., Johansen, A. {Protty, 2015 #259} | Mechanical prophylaxis after hip fracture: What is the risk of deep vein thrombosis? A retrospective observational study | BMJ Open | not comparative - DVT on which hip |
| Poster 38 | Rao N; Agarwal N; Aliga N; Ruroede K; Gnanapragasam G; Tancredi N; Srigiriraju P; Mekheil M; Afolarin H {Rao, 2014 #232} | Safety and effectiveness of anticoagulants in thromboprophylaxis after hip and knee replacement surgery at an inpatient rehabilitation hospital (2014) | PM and R Volume 6, Issue 9, Supplement, Page S195 | Combined TKR and THR |
| 26140896 | Ramanathan, R., Gu, Z., Limkemann, A. J., Chandrasekhar, S., Rensing, E., Mays, C., Duane, T. M. {Ramanathan, 2015 #256} | Association between interruptions in chemical prophylaxis and VTE formation | American Surgeon | combined medical and surgical admission |
| 23817755 | Raphael IJ, Tischler EH, Huang R, et al. {Raphael, 2014 #261} | Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty? | Clin Orthop Relat Res 2014;472(2): 492. | combined knee and hip |
| 24269095 | Raphael IJ and McKenzie JC and Zmistowski B and Brown DB and Parvizi J and Austin MS {Raphael, 2014 #24} | Pulmonary embolism after total joint arthroplasty: cost and effectiveness of four treatment modalities. | Combined TKR and THR | |
| 9471929 | Ryan DH, Crowther MA, Ginsberg JS, et al {Ryan, 1998 #105} | Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery | Ann Intern Med 1998;128:270–6 | No intervention of interest |
| 12820078 | Sachs RA, Smith JH, Kuney M, et al {Sachs, 2003 #101} | Does anticoagulation do more harm than good? A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty | J Arthroplasty 2003;18:389–95 | nRCS placebo comparison |
| 22592717 | Sajid Muhammad S; Desai Mital; Morris Richard W; Hamilton George {Sajid, 2012 #55} | Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis in postoperative surgical patients (2012) | Cochrane Database Syst Rev | Not surgery of interest |
| 20393944 | Salazar C A; Malaga G; Malasquez G {Salazar, 2010 #87} | Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement (2010) | Cochrane Database Syst Rev | Duplicate publication (no additional data) |
| 21777787 | Schade {Schade, 2011 #71} | Antithrombotic pharmacologic prophylaxis use during conservative and surgical management of foot and ankle disorders: a systematic review | Clin Podiatr Med Surg | Not surgery of interest |
| 25529031 | Shoda N and Yasunaga H and Horiguchi H and Fushimi K and Matsuda S and Kadono Y and Tanaka S {Shoda, 2015 #10} | Prophylactic effect of fondaparinux and enoxaparin for preventing pulmonary embolism after total hip or knee arthroplasty: A retrospective observational study using the Japanese Diagnosis Procedure Combination database. | Mod Rheumatol. 2015 Jul;25(4):625–9. | Combined TKR and THR |
| 17449088 | Shorr AF, Kwong LM, Sarnes M, et al {Shorr, 2007 #98} | Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis | Thromb Res 2007;121:17–24 | Combined TKR and THR |
| Silva Kanan P, Schwartsmann CR, Carbonera Boschin L, Conrad S, Faria Silva M{Kanan, 2008 #233} | Comparative study between rivaroxaban and enoxaparin in deep venous thromboembolism prophylaxis in patients submitted to total hip arthroplasty | Revista Brasileira de Ortopedia 2008;43:319–28 | Pre-2010 (presumably excluded by Uconn) | |
| Abstract page 21 | Singh S K; Kallhfallah A {Singh, 2012 #234} | The prevent trial-prevention of venous thromboembolism with enoxaparin vs rivaroxaban following hip and knee replacement surgeries (2012) | Internal Medicine Journal | Insufficient results data reported |
| Spiro TE, Johnson GJ, Christie MJ, et al {Spiro, 1994 #235} | Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery, Enoxaparin clinical trial group | Ann Intern Med 1994;121(2):81–89 | Pre-2010 (presumably excluded by Uconn) | |
| 25946985 | Squizzato A and Lussana F and Cattaneo M{Squizzato, 2015 #6} | Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty. | Duplicate publication (no additional data) | |
| 71809411 | Squizzato A; Lussana F; Cattaneo M | Incidence of post-operative arterial thrombosis in patients undergoing total hip or total knee arthroplasty treated with non-vitamin K antagonist oral anticoagulants or enoxaparin: A systematic review and a meta-analysis of the literature (2014) | Thrombosis Research | SR or MA without references (conference abstract) |
| Squizzato A; Lussana F; Cattaneo M | Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty: A meta-analysis (2015) | Italian Journal of Medicine | Duplicate publication (no additional data) | |
| 23324504 | Stewart DW and Freshour JE {Stewart, 2013 #44} | Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence. | Duplicate publication (no additional data) | |
| 24581264 | Sun Y and Chen D and Xu Z and Shi D and Dai J and Qin J and Qin J and Jiang Q {Sun, 2014 #19} | Deep venous thrombosis after knee arthroscopy: a systematic review and meta-analysis. | Duplicate publication (no additional data) | |
| 24007323 | Tahir F; Riaz H; Riaz T; Badshah M B; Riaz I B; Hamza A; Mohiuddin H {Tahir, 2013 #29} | The new oral anti-coagulants and the phase 3 clinical trials – a systematic review of the literature (2013) | Thrombosis Journal | No primary data |
| Tamir L, Hendel D, Neyman C, et al{Tamir, 1999 #236} | Sequential foot compression reduces lower limb swelling and pain after total knee arthroplasty | J Arthroplasty 1999;14:333 | Pre-2010 (presumably excluded by Uconn) | |
| noPMID 01 | Tangelder M | Inhibition of FVIII with TB-402 for the prevention of venous thromboembolism after total knee and hip replacement: Phase I–II results (2013) | Phlebolymphology | No results reported |
| 20383852 | Tasker A; Harbord R; Bannister G C {Tasker, 2010 #88} | Meta-analysis of low molecular weight heparin versus placebo in patients undergoing total hip replacement and post-operative morbidity and mortality since their introduction (2010) | Hip Int | Duplicate publication (no additional data) |
| 23328267 | Thomas {Thomas, 2013 #43} | Rivaroxaban: an oral factor Xa inhibitor | Clin Ther | No primary data |
| 18487854 | Thorey F, Stukenborg-Colsman C, Windhagen H, et al {Thorey, 2008 #95} | The effect of tourniquet release timing on perioperative blood loss in simultaneous bilateral cemented total knee arthroplasty: A prospective randomized study | Technology and Health Care 2008;16:85–92 | No intervention of interest |
| Tian HSF, Zhang K, Liu Y{Tian, 2007 #237} | Efficacy and safety of aspirin in prevention of venous thromboembolism after total joint arthroplasty | Zhonghua Yi Xue Za Zhi 2007;87:3349–52 | Pre-2010 (presumably excluded by Uconn) | |
| 25547937 | Touma L; Filion K B; Atallah R; Eberg M; Eisenberg M J {Touma, 2015 #9} | A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists (2015) | Am J Cardiol | Duplicate publication (no additional data) |
| 26184606 | Tsuda, K., Nishii, T., Sakai, T., Takao, M., Nakamura, N., Sugano, N. {Tsuda, 2016 #255} | Thrombophylaxis with low-dose, short-term fondaparinux after elective hip surgery | Journal of Thrombosis and Thrombolysis | NRCS N<750 |
| 70266427 | Turpie A G G; Agnelli G; Fisher W; George D; Kakkar A; Lassen M R; Mismetti P; Destree D; Mouret P {Turpie, 2014 #26} | Benefit-to-risk profile of the ultra-low-molecularweight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (vte): A meta-analysis of 3 major orthopaedic surgery studies (2010) | Pathophysiology of Haemostasis and Thrombosis | SR or MA without references (conference abstract) |
| Abstract 20 | Turpie A G G; Jamal W; Schmidt A; Lassen M R; Mantovani L G; Kreutz R; Haas S {Turpie, 2012 #238} | XAMOS: A non-interventional study comparing oral rivaroxaban with conventional regimens for thromboprophylaxis after major orthopaedic surgery of the hip and knee (2012) | British Journal of Haematology | Duplicate publication (no additional data) |
| Abstract 154 | Turpie A G G; Schmidt A; Lassen M R; Mantovani L G; Kreutz R; Holberg G; Haas S {Turpie, 2014 #239} | Rivaroxaban for thromboprophylaxis after total hip or knee replacement surgery: Comparison of outcomes of the XAMOS and record studies (2014) | American Journal of Hematology | Duplicate publication (no additional data) |
| Abstract 500 | Turpie A G G; Schmidt A; Lassen M R; Mantovani L; Kreutz R; Holberg G; Haas S {Turpie, 2014 #239} | Rivaroxaban for thromboprophylaxis after total hip or knee replacement surgery: Comparison of outcomes of the XAMOS and record studies (2012) | Blood. Conference: 54th Annual Meeting of the American Society of Hematology, ASH | Duplicate publication (no additional data) |
| 24154549 | Turpie AG and Haas S and Kreutz R and Mantovani LG and Pattanayak CW and Holberg G and Jamal W and Schmidt A and van Eickels M and Lassen MR {Turpie, 2014 #26} | A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. | Thromb Haemost. 2014 Jan;111(1):94–102 | Combined TKR and THR |
| Turpie AG, Bauer KA, Davidson BL, et al {Turpie, 2009 #240} | A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) | Thromb Haemost 2009; 101(1):68–76 | Pre-2010 (presumably excluded by Uconn) | |
| Turpie AG, et al {Turpie, 2009 #240} | Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial | Lancet 373 (9676) (2009) 1673–1680 | Pre-2010 (presumably excluded by Uconn) | |
| Turpie AG, Gallus AS, Hoek JA {Turpie, 2001 #241} | A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement | N Engl J Med 2001;344(9):619–625 | Pre-2010 (presumably excluded by Uconn) | |
| Turpie AGG, et al | BAY 59-7939: An oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement, A phase II dose-ranging study {Turpie, 2005 #242} | J Thromb Haemost 3 (11) (2005) 2479–2486 | Pre-2010 (presumably excluded by Uconn) | |
| 23355673 | Veen Lv and van Raay JJ and Gerritsma-Bleeker CL and Veeger NJ and Hulst Mv {Veen, 2013 #41} | Direct treatment comparison of Dabigatran and Rivaroxaban versus Nadroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomized pilot study (DARINA). | No results reported | |
| noPMID 08 | Velik-Salchner C; Oswald E; Innerhofer P; Streif W | Thrombin generation during major orthopedic surgery: Rivaroxaban versus enoxaparin for thromboprophylaxis (2011) | Hamostaseologie | Combined TKR and THR |
| Venker B; Ruparelia B; Lee E D; Nunley R; Gage B F {Venker, 2012 #243} | Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty (2012) | Pharmacotherapy | SR or MA without references (conference abstract) | |
| Abstract P509 | Verhamme P; Verhaeghe R; Ageno W; De Deene A; Glazer S; Prins M; Buller H; Jacquemin M {Verhamme, 2010 #244} | Single intravenous administration of TB-402 for the prophylaxis of VTE after total knee replacement surgery (2010) | Pathophysiology of Haemostasis and Thrombosis | Duplicate publication (no additional data) |
| Villasis-Keever M A; Rendon-Masias M E; Mould-Quevedo J F{Villasis-Keever, 2010 #245} | A meta-analysis of efficacy and safety of dalteparin in the prevention and treatment of venous thromboembolic disease (VTE) (2010) | Value in Health | SR or MA without references (conference abstract) | |
| 10067997 | Wakankar HM, Nicholl JE, Koka R, et al{Wakankar, 1999 #104} | The tourniquet in total knee arthroplasty | J Bone Joint Surg 1999;81-B:30–3 | No intervention of interest |
| 24717837 | Wang Z and Anderson FA Jr and Ward M and Bhattacharyya T{Wang, 2014 #18} | Surgical site infections and other postoperative complications following prophylactic anticoagulation in total joint arthroplasty. | Combined TKR and THR | |
| Westrich GH, Bottner F, Windsor RE, Laskin RS, Haas SB, Sculco TP {Westrich, 2006 #247} | VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty | J Arthroplasty 2006;21(6 suppl 2):139–143 | Pre-2010 (presumably excluded by Uconn) | |
| 18751828 | Westrich GH, Winiarsky R, Betsy M, et al{Westrich, 2006 #93} | Effect on deep venous thrombosis with flexion during total knee arthroplasty | HSS Journal 2006;2:148–53 | No intervention of interest |
| Williams JT, Palfrey SM {Williams, 1987 #246} | Cost effectiveness and efficacy of below knee against above knee graduated compression stockings in the prevention of deep vein thrombosis | Phlébologie 1988;41(4):809–11 | Pre-2010 (presumably excluded by Uconn) | |
| 8895639 | Williams-Russo P, Sharrock NE, Haas SB, et al{Williams-Russo, 1996 #107} | Randomized trial of epidural versus general anesthesia: outcomes after primary total knee replacement | Clin Orthop 1996;:199–208 | No intervention of interest |
| 26095331 | Wood R C 3rd; Stewart D W; Slusher L; El-Bazouni H; Cluck D; Freshour J; Odle B{Wood, 2015 #4} | Retrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data (2015) | Pharmacotherapy | No comparison of interest |
| 26026635 | Xie, J., Ma, J., Kang, P., Zhou, Z., Shen, B., Yang, J., Pei, F. {Xie, 2015 #257} | Does tranexamic acid alter the risk of thromboembolism following primary total knee arthroplasty with sequential earlier anticoagulation? A large, single center, prospective cohort study of consecutive cases | Thrombosis Research | thromboprophylaxis +/− tranexamic acid |
| 24352825 | Yassin M and Mitchell C and Diab M and Senior C{Yassin, 2014 #22} | The necessity of pharmacological prophylaxis against venous thromboembolism in major joint arthroplasty. | Combined TKR and THR |
- Excluded Studies - Venous Thromboembolism Prophylaxis in Major Orthopedic Surger...Excluded Studies - Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update
Your browsing activity is empty.
Activity recording is turned off.
See more...